New Therapy
A new clinical trial is offering hope for people with Charcot-Marie-Tooth (CMT) disease. Researchers tested a plasmid-based gene therapy designed to support nerve and muscle function. Unlike viral gene therapies, this treatment can be given multiple times without triggering an immune response—making it a promising option for chronic conditions like CMT. In a small Phase 1 trial in Seoul, South Korea, 12 participants with CMT type 1A received injections of the therapy over 104 days. The results? No serious side…